Shuangcheng Donates Medical Products to Support Fighting of COVID-19
2020-04-28 09:48
Facing the severe situation of fighting against COVID-19, Hainan Shuangcheng Pharmaceuticals Co., Ltd (the “company") pays close attention to the spread of the epidemic, performs its own role well in epidemic prevention and control, actively fulfills its social responsibility, and fully supports the fight against COVID-19.
On 25 January 2020, the company donated 4,000 vials of Thymalfasin for Injection to the frontline medical staff of First Affiliated Hospital to Hainan Medical University, Health Center of Nada, Danzhou, and Sanya Central Hospital and 800 vials of Thymalfasin for Injection to the frontline medical staff of Zhulin Town Hospital through Red Cross Society of Qichun county, Hubei province.
On 27 January 2020, the company donated 600 vials of Thymalfasin for Injection to Hainan medical team who volunteered to assist Hubei medical team.
On 6 February 2020, the company donated 10,000 vials of Thymalfasin for Injection to the frontline medical staff of Wuhan Jinyintan Hospital and Wuhan Lung Hospital and the frontline journalists who were reporting the epidemic on the spot.
So far, the company has donated 15,400 vials of Thymalfasin for Injection for fighting of COVID-19. The donated Thymalfasin for Injection is used to enhance the immunity of medical staff and journalist to COVID-19 so that they can better fight “the battle” on the front line of the epidemic.
Thymalfasin for Injection has been widely used and recognized in the field of immune adjustment, especially in antiviral and immune response enhancement. It has been approved to be listed in more than 30 countries in the world. Thymalfasin for Injection produced by the company is the only one of the same variety in China that has been approved by the EU country where the reference listed drug originates. It is also the first product of the same variety that has been applied for drug consistency evaluation in China. Its production line has passed the GMP inspections of the U.S. FDA and EMA for many times.
For more information about the product, please contact us.
On 25 January 2020, the company donated 4,000 vials of Thymalfasin for Injection to the frontline medical staff of First Affiliated Hospital to Hainan Medical University, Health Center of Nada, Danzhou, and Sanya Central Hospital and 800 vials of Thymalfasin for Injection to the frontline medical staff of Zhulin Town Hospital through Red Cross Society of Qichun county, Hubei province.
On 27 January 2020, the company donated 600 vials of Thymalfasin for Injection to Hainan medical team who volunteered to assist Hubei medical team.
On 6 February 2020, the company donated 10,000 vials of Thymalfasin for Injection to the frontline medical staff of Wuhan Jinyintan Hospital and Wuhan Lung Hospital and the frontline journalists who were reporting the epidemic on the spot.
So far, the company has donated 15,400 vials of Thymalfasin for Injection for fighting of COVID-19. The donated Thymalfasin for Injection is used to enhance the immunity of medical staff and journalist to COVID-19 so that they can better fight “the battle” on the front line of the epidemic.
Thymalfasin for Injection has been widely used and recognized in the field of immune adjustment, especially in antiviral and immune response enhancement. It has been approved to be listed in more than 30 countries in the world. Thymalfasin for Injection produced by the company is the only one of the same variety in China that has been approved by the EU country where the reference listed drug originates. It is also the first product of the same variety that has been applied for drug consistency evaluation in China. Its production line has passed the GMP inspections of the U.S. FDA and EMA for many times.
For more information about the product, please contact us.
